The Fraunhofer-Gesellschaft, on behalf of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, has signed an asset transfer agreement with Takeda GmbH to exclusively transfer its Surfactant and Continuous Powder Aerosolization (CPA) program assets to Fraunhofer ITEM.
The transfer includes the CPA technology for continuous aerosolization of powdery substances and the know-how to manufacture recombinant surfactant protein C, together with the associated intellectual property. The Fraunhofer ITEM is thus in a position to continue the development of therapies involving continuous inhalation various medications, begun 10 years ago.
Closing down its respiratory department, Takeda transferred its Surfactant and CPA program assets to Fraunhofer ITEM including the associated intellectual property. The CPA technology is the first non-invasive administration method for powdery surfactant drugs.
Surfactant drugs have to be administered to patients with surfactant deficiency, which is common, for example, in preterm in neonates. Furthermore, this therapeutic approach has been investigated in other acute and chronic life-threatening diseases such as acute lung injury and COPD.
Surfactant (“surface-active agent“) is secreted by certain lung cells und reduces surface tension in the alveoli, thereby preventing their collapse. Physical activity causes an increase, smoking a decrease in surfactant production. Fetal surfactant production starts in week 24 of gestation. Preterm neonates, in particular if born before week 34 of gestation, suffer from varying degrees of pulmonary surfactant deficiency, which may lead to neonate respiratory distress syndrome.
Surfactant-based therapy is the standard of care. Its use is limited, however, due to the currently invasive administration methodology. The CPA technology simplifies surfactant delivery to neonates and can also be used for children and adults. Recombinant surfactant protein C is the first recombinant surfactant protein suitable for use in synthetic surfactant drugs.
CPA is also a suitable technology to continuously deliver pulmonary high doses of non-soluble drugs to patients. In respiratory care, the standard of aerosolization for continuous inhalation is currently confined to different classes of nebulizers. In contrast, the CPA technology for the first time enables continuous inhaled administration of non-soluble drugs. In addition, it delivers a higher drug concentration to patients and enables a higher lung deposition rate.
Dr. Gerhard Pohlmann, Head of Medical Inhalation Technology at Fraunhofer ITEM with a 10+ year track record in CPA technology development, said: “As a long-standing partner in the CPA program, Fraunhofer ITEM is delighted to continue development of the surfactant and CPA technology platform. We are currently in the strategic process of reorganizing the program and selecting development partners.”
Dr. Gerhard Pohlmann; +49 511 5350-116
Dr. Cathrin Nastevska; +49 511 5350-225
The text of this press release can be found on our homepage at
Dr. Cathrin Nastevska | Fraunhofer Institute for Toxicology and Experimental Medicine
New insight into the brain’s hidden depths: Jena scientists develop minimally-invasive endoscope
27.11.2018 | Leibniz-Institut für Photonische Technologien e. V.
New China and US studies back use of pulse oximeters for assessing blood pressure
21.11.2018 | University of British Columbia
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Power and Electrical Engineering
14.12.2018 | Physics and Astronomy
14.12.2018 | Physics and Astronomy